Země: Jihoafrická republika
Jazyk: angličtina
Zdroj: South African Health Products Regulatory Authority (SAHPRA)
Medchem
PLASMOQUINE CAPSULES SCHEDULING STATUS Schedule 1 : Prophylaxis Schedule 4 : Treatment PROPRIETARY NAME (and dosage form): PLASMOQUINE CAPSULES COMPOSITION PLASMOQUINE capsules contain 200 mg chloroquine sulphate monohydrate which is equivalent to 146,7 mg chloroquine base. PHARMACOLOGICAL CLASSIFICATION A 20.2.6 Medicines against Protozoa. PHARMACOLOGICAL ACTION: Chloroquine sulphate is an anti-malarial agent with rapidly acting blood schizonticidal and some gametocyticidal activity. It is not effective against exoerythrocytic tissue stages of plasmodia. INDICATIONS Malaria prophylaxis in areas where chloroquine resistance is not encountered. Treatment of malaria where clinical symptoms and parasitaemia are rapidly controlled provided that the patient did not contract malaria in a chloroquine- resistant area and was not using chloroquine as prophlaxis for malaria. CONTRA-INDICATIONS Hypersensitivity to chloroquine. WARNINGS Plasmoquine should only be used during pregnancy if unavoidable and if the risk of malaria is more hazardous than the potential damage of chloroquine to the fetus. Chloroquine may temporarily affect visual accommodation and patients undergoing treatment should not take charge of vehicles or machinery until the effect of treatment is evident. Long-term, large-dose therapy may cause ocular disturbances (damage to eyesight) and for this reason opthalmological examinations are recommended every 3 to 6 months during treatment. Care is necessary in administering chloroquine to patients with impaired liver or renal function or with porphyria or psoriasis. Chloroquine should be used with extreme caution in epileptic patients as chloroquine may interfere with seizure control. Resistance of Plasmodium falciparum to chloroquine may develop. No malaria prophylaxis is fully effective and th Přečtěte si celý dokument